A therapeutically targetable mechanism of BCR-ABL-independent imatinib resistance in chronic myeloid leukemia

Genome-wide comparison of the transcriptomes of highly enriched normal and chronic myeloid leukemia stem and progenitor cell populations

(2015) Jonathan M. Gerber et al.   Oncotarget

Concise Review: Cancer Cells Escape from Oncogene Addiction: Understanding the Mechanisms Behind Treatment Failure for More Effective Targeting

(2014) Francesca Pellicano et al.   STEM CELLS

Activation of p53 by SIRT1 Inhibition Enhances Elimination of CML Leukemia Stem Cells in Combination with Imatinib

(2012) Ling Li et al.   CANCER CELL

Elf5 inhibits the epithelial–mesenchymal transition in mammary gland development and breast cancer metastasis by transcriptionally repressing Snail2

(2012) Rumela Chakrabarti et al.   NATURE CELL BIOLOGY

The Blk pathway functions as a tumor suppressor in chronic myeloid leukemia stem cells

(2012) Haojian Zhang et al.   NATURE GENETICS

HemaExplorer: a database of mRNA expression profiles in normal and malignant haematopoiesis

(2012) Frederik Otzen Bagger et al.   NUCLEIC ACIDS RESEARCH

ELF5 Suppresses Estrogen Sensitivity and Underpins the Acquisition of Antiestrogen Resistance in Luminal Breast Cancer

(2012) Maria Kalyuga et al.   PLOS BIOLOGY

Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival

(2011) A. Hamilton et al.   BLOOD

Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease

(2011) J.-C. Chomel et al.   BLOOD

Nilotinib and MEK Inhibitors Induce Synthetic Lethality through Paradoxical Activation of RAF in Drug-Resistant Chronic Myeloid Leukemia

(2011) Leisl M. Packer et al.   CANCER CELL

Forced expression of the histone demethylase Fbxl10 maintains self-renewing hematopoietic stem cells

(2011) Takaaki Konuma et al.   EXPERIMENTAL HEMATOLOGY

BCR-ABL1-independent PI3Kinase activation causing imatinib-resistance

(2011) Hilmar Quentmeier et al.   Journal of Hematology & Oncology

The MEK inhibitor PD184352 enhances BMS-214662-induced apoptosis in CD34+ CML stem/progenitor cells

(2011) F Pellicano et al.   LEUKEMIA

Comprehensive Predictive Biomarker Analysis for MEK Inhibitor GSK1120212

(2011) J. Jing et al.   MOLECULAR CANCER THERAPEUTICS

A framework for oligonucleotide microarray preprocessing

(2010) Benilton S. Carvalho et al.   BIOINFORMATICS

Genome-wide search identifies Ccnd2 as a direct transcriptional target of Elf5 in mouse mammary gland

(2010) Rosalba Escamilla-Hernandez et al.   BMC MOLECULAR BIOLOGY

Effective Targeting of Quiescent Chronic Myelogenous Leukemia Stem Cells by Histone Deacetylase Inhibitors in Combination with Imatinib Mesylate

(2010) Bin Zhang et al.   CANCER CELL

Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity

(2010) Amie S. Corbin et al.   JOURNAL OF CLINICAL INVESTIGATION

BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: A review

(2010) Xin An et al.   LEUKEMIA RESEARCH

ABL Tyrosine Kinases: Evolution of Function, Regulation, and Specificity

(2010) J. Colicelli   Science Signaling

Contribution of BCR–ABL-independent activation of ERK1/2 to acquired imatinib resistance in K562 chronic myeloid leukemia cells

(2009) Takeru Nambu et al.   CANCER SCIENCE

Loss-of-function genetic screens as a tool to improve the diagnosis and treatment of cancer

(2009) J Mullenders et al.   ONCOGENE

ERK2, but Not ERK1, Mediates Acquired and “De novo” Resistance to Imatinib Mesylate: Implication for CML Therapy

(2009) Clara I. Aceves-Luquero et al.   PLoS One

Early in vivo changes of the transcriptome in Philadelphia chromosome-positive CD34+ cells from patients with chronic myelogenous leukaemia following imatinib therapy

(2008) D Bruennert et al.   LEUKEMIA

PKC  regulates occludin phosphorylation and epithelial tight junction integrity

(2008) T. Suzuki et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA